Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Trial Details

NCT ID
NCT05061550
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Durvalumab
  • Oleclumab
  • Monalizumab
  • Dato-DXd
  • AZD0171
  • Carboplatin
Locations (sample)
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Los Angeles, California, United States|34.05223,-118.24368
  • Oakland, California, United States|37.80437,-122.2708
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Stuart, Florida, United States|27.19755,-80.25283

Key Eligibility Criteria

  • Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).
  • WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ and bone marrow function.
  • Provision of tumour samples (newly acquired or archival tumour tissue \[≤ 6 months old\]) to confirm Programmed death-ligand 1 (PD-L1) status, epid…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →